MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) announced the issuance of U.S. Patent No. 11,085,047 for its drug candidate Supera-CBD, aimed at treating substance addiction and neurodegenerative diseases. Supera-CBD, a synthetic cannabidiol derivative, is projected to be significantly more effective than plant-derived CBD in treating conditions such as anxiety and chronic pain. The patent strengthens the company’s intellectual property position, adding to its existing 11 patents for the MYMD-1 drug platform, and supports the advancement towards human clinical trials.
MyMD Pharmaceuticals (Nasdaq: MYMD) announced that its subsidiary, Oravax Medical, is set to initiate clinical trials for an oral COVID-19 vaccine, starting in Israel. This vaccine is designed for both standalone use and as a booster for previously vaccinated individuals. MyMD holds a 13% stake in Oravax and a 2.5% royalty on future net sales. The potential spin-off of Oravax could benefit MyMD shareholders, with Oravax's vaccine being a triple antigen candidate, possibly offering broader protection against mutations. A Phase 2 trial for MyMD's MYMD-1 is also anticipated by Q4 2021.
MyMD Pharmaceuticals (Nasdaq: MYMD) recently announced that its lead clinical compound, MYMD-1, has shown effectiveness in suppressing cytokine storms, a critical factor in COVID-19 severity. The drug inhibits TNF-α, potentially mitigating the immune system's overreaction that leads to severe outcomes. MYMD-1 is also being researched for COVID-19-related depression, with a Phase 2 trial in collaboration with a major medical school. The company aims to expedite MYMD-1's FDA approval through emergency programs, highlighting its dual focus on treating COVID-19 and extending healthy lifespan.
MyMD Pharmaceuticals (Nasdaq: MYMD) announced data from a study by Eurofins Discovery that indicates commonality between its lead compound MYMD-1 and three FDA-approved JAK inhibitors for treating autoimmune diseases. The JAK inhibitor market is currently valued at $11 billion, projected to exceed $300 billion by 2026. MYMD-1 is also a selective TNF-α inhibitor and can cross the blood-brain barrier, providing additional advantages for patients with chronic inflammation. The FDA has issued warnings for existing JAK inhibitors, highlighting the potential safety advantages of MYMD-1.
MyMD Pharmaceuticals has announced promising data from a study on MYMD-1, its lead compound, conducted by Eurofins Discovery. The study shows MYMD-1's significant anti-proliferative effects compared to leading TNF inhibitors, indicating its potential to treat autoimmune and age-related diseases. MYMD-1 effectively regulates the immune system by selectively inhibiting TNF-alpha, a driver of chronic inflammation, without the adverse effects seen in current therapies. MyMD plans further studies as it progresses toward Phase 2 clinical trials.
MyMD Pharmaceuticals (Nasdaq: MYMD) has been approved for inclusion in the Russell Microcap® Index, effective post-market on June 28, 2021. This annual reconstitution enhances the company's visibility within the investment community and opens opportunities for new investors.
The Russell indexes are a significant benchmark, with over $10.6 trillion in assets linked to them, increasing MyMD's profile among institutional investors. The company aims to extend healthy lifespan through its clinical-stage drug platforms, MYMD-1 and Supera-CBD.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company, has announced the appointment of David Rini to its Scientific Advisory Board. Rini, a Professor at Johns Hopkins University with extensive experience in medical illustration, expressed his enthusiasm for collaborating on the company's therapeutic platforms. MyMD focuses on two platforms: MYMD-1, targeting autoimmune diseases and aging, and Supera-CBD, a novel synthetic CBD derivative aimed at the growing market. A presentation relevant to these developments is scheduled for May 17th at 4:15 PM ET.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) announced a conference call scheduled for May 17th at 4:15 p.m. ET to discuss its clinical and drug development plans. The call can be accessed via a registration link or by dialing in. The company is focused on two therapeutic platforms: MYMD-1, aimed at treating autoimmune diseases, and Supera-CBD, a synthetic derivative of CBD targeting key receptors. The press release includes a cautionary statement regarding forward-looking statements that highlight various risks associated with MyMD's pharmaceutical candidates.
MyMD Pharmaceuticals, a clinical stage pharmaceutical company (Nasdaq: MYMD), announced research findings on its compound Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit. The research from Johns Hopkins University highlights Supera-CBD's potential for treating psychiatric disorders by targeting the cannabinoid receptor type 2. Preliminary studies show Supera-CBD has strong anxiolytic effects and binds to CB2 with nearly four times the affinity of CBD. The presentation is scheduled for April 28, 2021, at 4:15 p.m. ET.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) announced that the USPTO has issued a Notice of Allowance for its patent application regarding Supera-CBD, a synthetic cannabinoid compound aimed at treating substance addiction and other disorders. This patent recognizes Supera-CBD's significant efficacy in inhibiting cannabinoid receptor type 2 (CB2), essential for managing neuroinflammatory and neurodegenerative diseases. The compound demonstrates 7-8x greater effectiveness than plant-derived CBD in specific therapeutic functions. MyMD is advancing plans for human clinical trials to evaluate Supera-CBD's potential in treating anxiety, chronic pain, and seizures.